Artiva Biotherapeutics (NASDAQ:ARTV) CEO Fred Aslan Sells 23,429 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,429 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total transaction of $255,844.68. Following the completion of the sale, the chief executive officer directly owned 1,449,765 shares in the company, valued at approximately $15,831,433.80. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Artiva Biotherapeutics Trading Down 0.8%

Shares of ARTV traded down $0.09 during trading hours on Wednesday, reaching $10.79. 325,035 shares of the company’s stock traded hands, compared to its average volume of 375,371. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The stock has a market cap of $527.52 million, a PE ratio of -3.27 and a beta of 2.18. The firm’s 50 day simple moving average is $10.62 and its 200-day simple moving average is $8.88.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARTV has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Finally, Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in Artiva Biotherapeutics in the second quarter worth about $79,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics during the 2nd quarter valued at approximately $58,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets raised its position in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.